Cargando…

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial

AIMS: In the EMPA‐REG OUTCOME trial, in patients with type 2 diabetes and established atherosclerotic cardiovascular (CV) disease, empagliflozin vs. placebo reduced the risk of hospitalization for heart failure (HHF) by 35%, CV death/HHF by 34%, and CV death by 38%, with an early separation of the c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verma, Subodh, Leiter, Lawrence A., Zinman, Bernard, Sharma, Abhinav, Mattheus, Michaela, Fitchett, David, George, Jyothis, Ofstad, Anne Pernille, Kosiborod, Mikhail N., Wanner, Christoph, Inzucchi, Silvio E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Short Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318423/ https://www.ncbi.nlm.nih.gov/pubmed/34132492 http://dx.doi.org/10.1002/ehf2.13374

Ejemplares similares

Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
por: Inzucchi, Silvio E, et al.
Publicado: (2020)

Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial
por: Vaduganathan, Muthiah, et al.
Publicado: (2021)

Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME(®) trial
por: Fitchett, David, et al.
Publicado: (2020)

Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA‐REG OUTCOME trial
por: Verma, Subodh, et al.
Publicado: (2020)

Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome: Analysis of EMPA-REG OUTCOME using REDUCE-IT criteria
por: Verma, Subodh, et al.
Publicado: (2023)

Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial
por: Ferreira, João Pedro, et al.
Publicado: (2020)

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial
por: Fitchett, David, et al.
Publicado: (2021)

Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial
por: Ferreira, João Pedro, et al.
Publicado: (2020)

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
por: Pellicori, Pierpaolo, et al.
Publicado: (2020)

Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial
por: Ferreira, João Pedro, et al.
Publicado: (2021)

Impact of polyvascular disease with and without co‐existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA‐REG OUTCOME
por: Verma, Subodh, et al.
Publicado: (2021)

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
por: Verma, Subodh, et al.
Publicado: (2018)

Association between uric acid levels and cardio‐renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA‐REG OUTCOME
por: Verma, Subodh, et al.
Publicado: (2020)

Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
por: Ferreira, João Pedro, et al.
Publicado: (2021)

Bladder cancer in the EMPA-REG OUTCOME trial
por: Kohler, Sven, et al.
Publicado: (2017)

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial
por: Fitchett, David, et al.
Publicado: (2019)

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(®) trial
por: Fitchett, David, et al.
Publicado: (2016)

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
por: Zinman, Bernard, et al.
Publicado: (2014)

Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
por: Sattar, Naveed, et al.
Publicado: (2018)

Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
por: Ceriello, Antonio, et al.
Publicado: (2020)

Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
por: Waijer, Simke W., et al.
Publicado: (2020)

Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME(®)
por: Langslet, Gisle, et al.
Publicado: (2020)

RF16 | PSUN155 Empagliflozin and the risk of nephrolithiasis
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2022)

Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA‐REG OUTCOME trial with a focus on Asia
por: Ji, Qiuhe, et al.
Publicado: (2021)

The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non‐Asian populations of the EMPA‐REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease
por: Kaku, Kohei, et al.
Publicado: (2022)

Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2022)

Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure
por: Reifsnider, Odette S., et al.
Publicado: (2020)

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
por: Zinman, Bernard, et al.
Publicado: (2017)

Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?
por: Ampudia-Blasco, Francisco Javier, et al.
Publicado: (2017)

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME(®) trial
por: Kadowaki, Takashi, et al.
Publicado: (2019)

Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial
por: Alzaid, Aus
Publicado: (2017)

Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015
por: Neeland, Ian J., et al.
Publicado: (2021)

Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes
por: Ruggenenti, Piero, et al.
Publicado: (2021)

Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2023)

Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis
por: Garg, Vinay, et al.
Publicado: (2020)

Cost‐effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA‐REG OUTCOME trial
por: Kansal, A., et al.
Publicado: (2019)

Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
por: Hundertmark, Moritz J., et al.
Publicado: (2021)

The EMPA-REG outcome study: critical appraisal and potential clinical implications
por: Perseghin, Gianluca, et al.
Publicado: (2016)

Vascular legacy: HOPE ADVANCEs to EMPA-REG and LEADER: A Surprising similarity
por: Kalra, Sanjay, et al.
Publicado: (2017)

SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review
por: Rastogi, Ashu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_iugke7fduv49ivpccu8jdmo0ts